Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced the appointment of Dr. Gary A. Shangold as chief medical officer (CMO), effective immediately.
The company stated that Dr. Shangold brings extensive experience across all phases of drug development to the role. Previously, he served as CMO of Enteris BioPharma and, prior to that, was CMO and EVP of research and development for Xanodyne Pharmaceuticals. Dr. Shangold was also the president and CEO of NovaDel Pharma.
In a statement, Stephan Stamp, CEO and CFO of Biodexa, said, “I am delighted to welcome Gary to the team. As Biodexa moved toward the later clinical stages, including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists with Gary’s knowledge and experience. I have worked with Gary before at Xanodyne where he was instrumental in securing two NDAs.”
